We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals

270 hedge funds and large institutions have $1.74B invested in Recursion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 111 increasing their positions, 53 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 53

88% more capital inflows, than outflows

Capital inflows: $190M | Capital outflows: $101M

4% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 45

0% more funds holding

Funds holding: 270 → 270 (0)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

15.27% less ownership

Funds ownership: 109.46% → 94.19% (-15%)

42% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $19.8M

Holders
270
Holders Change
–
Holders Change %
0%
% of All Funds
3.86%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
47
Increased
111
Reduced
53
Closed
45
Calls
$11.4M
Puts
$19.8M
Net Calls
-$8.4M
Net Calls Change
+$1.56M

RXRX Hedge Fund Activity: Q3 2024 in Review

270 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2024, worth a combined $1.74B — down 7.7% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RXRX positions and 45 closed out — a net gain of 2 holders — while 111 added to existing stakes and 53 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $33.2M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $21.8M sold.

  • 270 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $1.74B of Recursion Pharmaceuticals stock for Q3 2024, down 7.7% quarter-over-quarter.
  • 47 funds opened new Recursion Pharmaceuticals positions in Q3 2024 and 45 closed out, a net change of +2 holders.
  • The largest Recursion Pharmaceuticals buyer in Q3 2024 was ARK Investment Management, an estimated $33.2M added.
  • The largest Recursion Pharmaceuticals seller in Q3 2024 was Laurion Capital Management, an estimated $21.8M sold.

Based on aggregated 13F filings for Q3 2024.